Treatment Approaches to Mycobacterium abscessus Pulmonary Disease

被引：11

作者：

Holt, Michael R. ^{[1
,2
,6
]}

Baird, Timothy ^{[3
,4
,5
]}

机构：

[1] Univ Queensland, Gallipoli Med Res Fdn, Brisbane, Qld, Australia

[2] Royal Brisbane & Womens Hosp, Dept Thorac Med, Butterfield St, Herston, Qld, Australia

[3] Sunshine Coast Hlth Inst, Sunshine Coast, Qld, Australia

[4] Univ Sunshine Coast, Sunshine Coast, Qld, Australia

[5] Sun shine Coast Univ Hosp, Dept Resp Med, 6 Doherty St, Sunshine Coast, Qld 4575, Australia

[6] Royal Brisbane & Womens Hosp, Dept Thorac Med, Butterfield St, Herston, Qld 4029, Australia

来源：

CLINICS IN CHEST MEDICINE | 2023年 / 44卷 / 04期

关键词：

M abscessus'; Nontuberculous mycobacteria; Pulmonary disease; Treatment; IN-VITRO ACTIVITY; NONTUBERCULOUS MYCOBACTERIA; TREATMENT OUTCOMES; LUNG-DISEASE; AMIKACIN; TIGECYCLINE; RESISTANCE; SUSCEPTIBILITY; CLOFAZIMINE; CHELONAE;

D O I：

10.1016/j.ccm.2023.06.010

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

MAB-PD presents a significant therapeutic challenge due to the poor treatment outcomes and toxicity of current guidelines-based therapy. Macrolide susceptibility is a key prognostic factor and should be protected by adequate companion drugs during intensive and continuation phases. Optimal drug combinations, duration of therapy, and management of refractory disease are unknown. Fortunately, there are multiple emerging therapeutic candidates to address the unmet need for efficacious and tolerable treatment options.

引用

页码：785 / 798

页数：14